Integra Holdings, an investment company exclusively focused on life science innovations originating from the Hebrew University, has made the first close of a $25-million funding round led by Temasek Holdings.
Temasek, Singapore’s state investor, led the round with a $15-million investment and was joined by UK-based Arie Capital, which made an initial investment of $2 million. The Israeli Teachers’ and Kindergarten’s Study Funds, one of Integra’s current shareholders, also participated in this financing round.
The funds raised will be used to support Integra’s existing portfolio companies and add new companies using promising technology originating from the Hebrew University of Jerusalem.
“I am proud to welcome Temasek and Arie Capital to our circle of investors,” said Dr. Liana Patt, CEO of Integra Holdings. “This strategic investment reinforces the global recognition of the Hebrew University’s exceptional contribution to life science innovations and Integra’s robust and growing portfolio”.
Founded in 2012 by Yissum, the Technology Transfer Company of the Hebrew University, Integra exclusively selects life science companies and focuses on proprietary innovations in the fields of biotechnology, pharmaceuticals, diagnostics and medical devices. It assists portfolio firms with strategic planning, business development and research and development guidance needed for go-to-market operations and technology commercialisation.
Recent years have seen Temasek grow its exposure to Israel It established Red Dot Capital Partners in early 2016, a $150 million fund providing growth capital to Israel‐based technology companies that plan to expand to Asia.
Earlier this year, it was also reported that Vertex Ventures, the venture capital unit of Temasek, was also looking to raise a venture fund with a corpus of about $150 million targeting the Israeli cybersecurity sector in 2018.